Hemodynamic effects of the class III antiarrhythmic drug, d-Sotalol, in patients with congestive heart failure

American Journal of Cardiology

Volumn 78, Issue 12, 1996, Pages 1411-1415

  Gottlieb, Stephen S ^a   Singh, Steven ^b   Munger, Mark ^b   Eichhorn, Eric J ^b   Llgenfritz, John ^b   Hanyok, James ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; SOTALOL;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; SOTALOL; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0030589274     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00640-6     Document Type: Article

References (20)

1. Packer M, Lee WH, Medina N, Yushak M, Bernstein JL, Kessler PD. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol 1987;10:1303-1311.
2. Gottlieb SS, Kukin ML, Medina N, Yushak M, Packer M. Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure. Circulation 1990;81:860-864.
3. Gottlieb SS, Weinberg MC. Cardiodepressant effects of mexiletine in patients with severe left ventricular dysfunction. Eur Heart J 1992;13:22-27.
4. Fink RHA, Stephenson DG. Ca2+-movements in muscle modulated by the state of the K+-channels in the sarcoplasmic reticulum membranes. Pflügers Arch 1987;409:374-380
5. Beregi J, Excande D, Coudray N, Mery P, Mestre M, Chemla D, Lecarpentier Y. Positive inotropic effects of RP 62719, a new pure class III antiarrhythmic agent, on guinea pig myocardium. J Pharmacol Exp Ther 1992;263:1369-1376.
6. Tande PM, Refsum H. Class III antiarrhythmic action linked with positive inotropy: effects of the d- and l-isomer of sotalol on isolated rat atria at threshold and suprathreshold stimulation. Pharmacol Toxicol 1988;62:272-277.
7. Lathrop DA. Electromechanical characterization of the effects of racemic sotalol and its optical isomers on isolated canine ventricular trabecular muscles and Purkinje strands. Can J Physiol Pharmacol 1985;63:1506-1512.
8. Seipel L, Hoffmeister HM. Inotropic and haemodynamic effects of d- and d,1-sotalol: comparison with other antiarrhythmics. Eur Heart J 1993;14(suppl H):36-40.
9. Mortensen E, Yang T, Refsum H. Class III antiarrhythmic action and inotropy: effects of dofetilide in acute ischemic heart failure in dogs. J Cardiovasc Pharmacol 1992;19:216-221.
10. Gwilt M, Blackburn KJ, Burges RA, Higgins AJ, Milne AA, Solca AM. Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs. Eur J Pharmacol 1992;215:137-144.
11. Twidale N, Roberts-Thomson P, McRitchie RJ. Comparative hemodynamic effects of amiodarone, sotalol, and d-sotalol. Am Heart J 1993;126:122-129.
12. Stambler BS, Gottlieb SS, Singh BN, Ramanathan KB, Ogilby JD, Ellenbogen KA. Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardio-depressant effects, J Am Coll Cardiol 1995;26:1679-1684.
13. Tham TCK, MacLennan BA, Burke MT, Harron DWG. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans. J Cardiovasc Pharmacol 1993;21:507-512.
14. Spence SG, Vetter C, Hoe CM. Effects of the class III antiarrhythmic, dofetilide (UK-68,798) on the heart rate of midgestation rat embryos, in vitro. Teratology 1994;49:282-292.
15. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am Heart J 1992;123:1220-1224.
16. Waldo AL, Camm AJ, deRuyter H, Freidman PL, MacNeil DJ, Pitt B, Pratt CM, Rodda BE, Schwartz PJ. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). Am J Cardiol 1995;75:1023-1027.
17. Poirier JM, Jaillon P, Lecocq V, Lecocq V, Ferry A, Cheymol G. The pharmacokinetics of d-sotalol and d,1-sotalol in healthy volunteers. Eur J Clin Pharmacol 1990;38:579-582.
18. Singh BN, Kehoe R, Woosley RL, Scheinman M, Quart B. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group. Am Heart J 1995;129:87-97.
19. Bristow MR, Lowes BR. Low-dose inotropic therapy for ambulatory heart failure. Coron Artery Dis 1994;5:112-118.
20. Gottlieb SS, Weinberg MC. Hemodynamic and neurohormonal effects of quinidine in patients with severe left ventricular dysfunction secondary to coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1991;67:728-731.